Skip to main content

When your patient need access to NULIBRY, urgency is critical

ForgingBridges | NULIBRY Access and Support program is your source for helping your patients receive NULIBRY—now and as they grow

At Origin, we strive to provide NULIBRY to children who need it, which is why we created ForgingBridges | NULIBRY. It is a comprehensive set of support programs dedicated to helping children get access to NULIBRY. Our team of specialists coordinates with insurance companies throughout the benefits verification and coverage process. ForgingBridges | NULIBRY also provides tools and resources to help facilitate the access process.

ForgingBridges | NULIBRY is committed to providing affordability options for NULIBRY

When your patient joins ForgingBridges | NULIBRY, they will be evaluated for a variety of programs designed to help improve access to NULIBRY.

ForgingBridges | NULIBRY also supports your patients by:

  • Conducting benefits investigations and providing support regarding prior authorizations and appeals
  • Offering a variety of patient support programs based on patient's insurance coverage and affordability challenges
  • Supplying educational resources

For example letters, please see below:

Appeals Summary Letter
forging bridges access support program logo

ForgingBridges | NULIBRY
Access and Support

For questions or additional info, give us a call. Our support team is ready to help.

Call 1-888-55BRIDGE

Monday-Friday, 8 am-8 pm ET

The support you need starts here.

How to Get NULIBRY >



NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.



Potential for Photosensitivity

NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.


The most common adverse reactions in NULIBRY-treated patients were infusion catheter–related complications (89%), pyrexia (fever) (78%), viral infection (56%), pneumonia (44%), otitis media (ear infection) (44%), vomiting (44%), and cough/sneezing (44%). Adverse reactions for rcPMP-treated patients were similar to the NULIBRY-treated patients.


Please read the FDA-approved NULIBRY Prescribing Information and Instructions for Use and follow the instructions on how to prepare and administer NULIBRY.

NULIBRY has a potential for photosensitivity; see Warnings and Precautions. Seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

Please see full Prescribing Information for NULIBRY.